Gelatin hydrogel microspheres (GHMs) have been reported as novel non-viral vectors for gene or protein delivery (GHM therapy). However, the components of an effective catheterbased delivery strategy for GHM therapy are unknown. We evaluated the effectiveness of three catheter-based strategies for cardiac GHM therapy: (1) antegrade injection (AI) via coronary arteries; (2) retrograde injection (RI) via coronary veins; and (3) direct myocardial injection (DI) via the coronary sinus. AI distributed microspheres homogeneously throughout the target area with 73711% retention. RI scattered microspheres non-homogenously with 2278% retention. DI distributed microspheres in the needle-advanced area with 47714% retention. However, despite high efficiency, AI did not show biological effects of inducing angiogenesis from basic fibroblast growth factor bound to GHMs. Furthermore, focal micro-infarctions, owing to micro-embolism of aggregated GHMs into small coronary arterioles, were detected in the AI group. Conversely, only RI and DI groups displayed increased coronary flow reserve. DI groups also demonstrated increased capillary density. These results suggest that RI and DI are effective for cardiac GHM therapy, while AI appears inappropriate owing to the risk of focal infarctions.
Introduction
Despite recent advances in pharmacotherapy and interventional treatments, cardiovascular disease remains a leading cause of mortality in developed countries. 1 Novel therapies including cell and gene transfer are being evaluated. 2, 3 However, the biosafety of viral vectors has not yet been established, and the half-life of naked plasmid deoxyribonucleic acid is insufficient for in vivo effectiveness.
Tabata et al. 4 developed gelatin hydrogel microspheres (GHMs) as novel non-viral vectors for gene and/or protein delivery. 4 GHMs can hold genes or proteins electrostatically, and therapeutic agents bound to GHMs can be gradually released for extended periods in vitro or in vivo in accordance with the well-defined process of GHM biodegradation. 4 GHMs can be modified to provide diameters varying from 10 to 4100 mm, or can be made into sheets. As gelatin is already used clinically and its safety is well established, gene or protein therapies using GHMs as non-viral vectors (GHM therapy) would be readily applicable for clinical use.
Several studies have reported the efficacy of GHM therapy in small or large animal models of cardiovascular diseases. [5] [6] [7] [8] [9] However, methods to deliver GHMs to the heart have previously been limited to an open chest surgical technique. As cardiac GHM therapy would be applied to patients with impaired cardiac function or severe ischemic heart disease, a catheter-based strategy would be beneficial for GHM therapy. Currently, however, the components of an effective catheter-based strategy for GHM therapy remains to be defined.
The purpose of this study was to evaluate the effectiveness of catheter-based strategies for delivering GHMs to porcine heart: (1) antegrade injection (AI) via coronary arteries; (2) retrograde injection (RI) via coronary veins; and (3) direct myocardial injection (DI) via the coronary sinus (Figure 1a-c) . The effectiveness of each method was evaluated by the ability to deliver 10-mm microspheres to the heart, and by the subsequent induction of angiogenic biological effects resulting from recombinant basic fibroblast growth factor (bFGF) incorporated with GHMs.
Results
GHMs or the same size of red-fluorescent microspheres were injected into 33 porcine hearts (n ¼ 10 for each catheter-based strategy, and n ¼ 3 for sham GHM-injection). All 33 injections were performed without encountering any adverse events, including no-flow phenomenon, sustained arrhythmia, and cardiac tamponade. No significant changes in electrocardiography were detected during injections.
Distribution and retention of microspheres in the heart
Numbers of 10-mm red-fluorescent microspheres displayed linear correlations with signal intensity (Y ¼ 0.0242X+142.49, R 2 ¼ 0.97; where Y ¼ signal intensity and X ¼ numbers of microspheres retained in the heart). Distributions of 10-mm fluorescent microspheres are shown in Figure 2 . Microspheres were broadly and homogeneously distributed within the target area with AI, but were non-homogenously scattered with RI, and were distributed in the needle-advanced area with DI.
The percentage of microspheres retained in the heart was highest for AI (73711%), followed by DI (47714%) and RI (2278%) (Figure 3 ). All differences in percentage retention between the three groups were significant (AI vs RI, Po0.001; AI vs DI, Po0.01; RI vs DI, Po0.01).
Aggregation of GHMs in suspension
When injected GHMs are suspended into 5 ml of saline, approximately 10% of GHMs were detected to aggregate together. As well, 1% of total injected GHMs formed clusters greater than 20 mm in size.
Systemic leakage of microspheres
No signals were detected from the liver, kidneys, or spleen. However, signals from the lungs were seen in five of five animals in the RI group, three of five animals in the DI group, and none of the five animals in the AI group.
Induction of angiogenesis
Effectiveness to induce angiogenesis was evaluated in 18 animals (n ¼ 5 for each group, and three for sham GHMinjection group). In one of five animals in the AI group, coronary flow reserve could not be measured because of mechanical failure of the device. No significant differences in coronary flow reserve ratio were noted between any groups at baseline. At 1 week after injection of GHMs incorporating bFGF, coronary flow reserve ratio was increased in both the RI group (from 1.070.1 to 1.270.1, n ¼ 5; Po0.05) and DI group (1.070.0 to 1.270.1, n ¼ 5; Po0.05), whereas no increase in coronary flow reserve ratio was identified for the AI group (1.070.1 at both time points, n ¼ 4) as well as the sham GHM-injection group (1.070.1 at both time points, n ¼ 3) (Figure 4a-d) . The change of absolute values of coronary flow reserve in the left anterior descending coronary (Figure 4f ).
Focal micro-infarctions
Although no significant electrocardiographic changes or slow-flow phenomenon were detected during injections, several focal micro-infarctions (1.370.3% of area injected) were found in target tissues for the AI group (n ¼ 5) (Figure 5a ). Furthermore, aggregated GHMs were trapped in myocardial arterioles rather than capillaries (Figure 5b ). No tissue damage was seen in the RI or DI groups (data not shown).
Discussion
GHM therapy can offer an attractive option for treatment of cardiovascular disease. [5] [6] [7] [8] [9] As gelatin is already used clinically and its safety is established, GHM therapy would be readily used for clinical application. However, catheter-based strategies for effective cardiac GHM therapy remain to be defined. The present study is the first evaluation of effectiveness for three catheter-based strategies that could be applied to cardiac GHM therapy. The study's findings suggest that RI and DI represent effective strategies for GHM therapy, whereas AI appears inappropriate owing to the risk of focal infarctions.
A catheter-based strategy is an attractive approach to cardiac therapy, owing to the reduced invasiveness compared to open surgical techniques. Various strategies have been investigated to achieve cardiac gene transfer using viral vectors. 10, 11 However, numerous differences in characteristics exist between GHMs and viral vectors. GHM sizes are in the order of micrometers, whereas viral vector sizes are in the order of nanometers. GHMs (f) Capillary density ratio at 1 week after injection of GHMs with bFGF (n ¼ 5 for each group). DI showed higher capillary density compared to AI (ANOVA, *Po0.05). LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery. Coronary flow reserve and capillary density in the LCX were used as reference to obtain the coronary flow reserve ratio or the capillary density ratio, respectively. Data are expressed as mean7s.d.
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K Hoshino et al are retained in the heart purely owing to mechanical interactions, whereas viral vectors can be captured through receptors on cardiac, vascular, and endothelial cells. We therefore considered that several catheter-based strategies could be feasible for GHM therapy. Indeed, the present study demonstrated that AI is inappropriate for GHM therapy owing to the risk of micro-embolism, whereas AI is reportedly an effective strategy for gene therapy using viral vectors. 10 In contrast, both RI and DI appeared effective for inducing biological effects in the form of angiogenesis owing to the bFGF delivered with GHMs.
We investigated the effectiveness of each catheterbased strategy to deliver 10-mm microspheres to the heart. Although AI distributed 10-mm microspheres homogeneously throughout the target area with 470% retention, risk of micro-embolism was increased. RI scattered 10-mm microspheres non-homogeneously with about 20% retention, and DI distributed microspheres in the needle-advanced area with about 50% retention. The retention percentage of microspheres injected with RI seemed too low to be effective, but, interestingly, is equivalent to that of the open surgical injection reported previously. 12 Open surgical injection have been reported to result in about 15% retention for 15-mm neutronactivated microspheres in the heart. 12 As open surgical injection has been used for effective local drug delivery to the myocardium, it is no wonder that RI strategy demonstrated effective induction of angiogenesis from the GHM/bFGF complex despite only 20% retention. Trans-left ventricular injection has also been reported to be associated with about 40% retention of microspheres, 12 comparable to this study's data for DI. The present study also demonstrated that AI is inappropriate for GHM therapy owing to the risk of micro-embolism, whereas AI is reportedly an effective strategy for gene therapy using viral vectors. 10 In contrast, both RI and DI appeared effective for inducing biological effects in the form of angiogenesis owing to the bFGF delivered with GHMs.
In addition, both RI and DI showed evidence of systemic leakage to the lungs, which may limit clinical applications depending on the genes or proteins injected. Microspheres injected with RI or DI leaked out from the heart through the coronary sinus and were probably trapped in the lungs at the pre-capillary level. Angiogenic growth factors are known to be associated with a potential risk of inducing tumor growth or exacerbating proliferative diseases. 13 No macroscopic abnormalities were detected in the lungs, but careful attention should be paid to this potential risk, particularly when RI or DI is applied for clinical cardiac GHM therapy.
Antegrade injection for GHM therapy
AI is a modification of conventional interventional methods and is thus easily applied to gene or protein delivery in clinical applications. Prior studies with AI using pre-capillary-sized microspheres have reported local non-invasive delivery of drugs over an extended period of time without any damage to the heart. Successful retention of 460% of injected microspheres in the heart were documented.
14 This was consistent with our findings. In the present study, AI could deliver 10-mm microspheres broadly and homogeneously with 470% retention in the target area.
However, despite high uptake and homogenous distribution, AI did not show any biological effectiveness. Furthermore, an important deleterious side effect of this delivery strategy was also documented: there was evidence of micro-infarctions and the latter are considered the most likely major contributing mechanism for the lack of increase in coronary flow reserve. Although the 10-mm microspheres used in the present study were slightly greater in size than the 7-mm microspheres used by Arras et al., 14 this difference in size was considered negligible and unlikely to prove critical in terms of tissue damage. The discrepancy in findings of tissue damage may thus be associated with differences in microsphere composition. GHMs in this study were biodegradable gelatin microspheres, whereas those used by Arras et al. were non-biodegradable resin microspheres. The gelatin component can lead GHMs to aggregate much more easily with each other when compared to resinmade microspheres. Although careful mixing of GHMs was performed in an attempt to prevent aggregation, approximately 1% of total GHMs were detected to form clusters greater than 20 mm in size. Furthermore, histology revealed GHMs had aggregated with one another. The latter became entrapped in small arterioles in vivo (Figure 5b) .
Although the percentage (1-2%) of microinfarction area at the injection area was not striking, when taking it into account that GHM therapy will be likely applied to patients with impaired cardiac function and/or severe ischemic heart disease, this potential risk cannot easily dismissed. According to our findings, given this delivery strategy's increased risk of micro-infarctions, AI should be considered inappropriate for GHM therapy. Future research should focus on technological improvements to prevent the aggregation of GHMs. 
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Retrograde injection via coronary vein for GHM therapy
Investigations into therapeutic approaches for myocardial gene or protein delivery have previously focused on coronary venous access. [15] [16] [17] The present study demonstrated that RI is also effective for GHM therapy to the heart. GHMs delivered via RI released bFGF and effectively induced angiogenesis in the target area without causing tissue damage in the heart.
The present study demonstrated that coronary flow reserve in the area injected with GHM/bFGF complex by RI increased significantly. In contrast, histological assessment did not show any increase in capillary density. This discrepancy can be explained by technique used to measure capillary density. The distribution of the RI-injected GHM/bFGF complex was likely nonhomogeneous. However, the sampling technique might have been suboptimal to fully document the resulting angiogenesis, as only one sample was taken in and around the RI-injected area. Therefore, coronary flow reserve would be a better maker of induced angiogenesis by this particular delivery strategy.
Some GHMs injected by RI might have aggregated and occluded post-capillary veins, as seen in the precapillary arteries with AI. However, unlike the AI group, tissue damage was not apparent in the target area in the RI group. This may be attributed to the anatomical complexity of coronary venous drainage systems. Numerous anastomoses and side channels are present in the epicardial coronary venous system. About a third of the blood coming to the LAD reportedly drains into the coronary sinus via circumflex veins instead of the anterior interventricular vein, which runs parallel to the LAD. 18 Moreover, another coronary venous drainage system, the Thebesian venous system, drains coronary venous flow directly into the cardiac chamber. 19 These two coronary venous drainage systems display numerous communications with each other. Therefore, even if aggregated GHMs occlude pre-capillary veins, coronary venous flow might not be interrupted owing to the highly redundant nature of coronary venous drainage networks.
The efficiency of RI in delivering GHMs to the heart was the lowest among the three delivery strategies. About 80% of 10-mm microspheres injected via RI leaked out of the heart and were trapped in the lungs. When considering clinical applicability, further improvements in RI efficiency are required. To improve efficiency, timing of injection may be a key factor, and suction of blood after the injection seems to represent one solution to avoid leakage. 20 Pressure-regulated retroinfusion, which controls injection timing in systole, with subsequent suction of blood, reportedly improves efficacies of RI for gene therapy or therapeutic angiogenesis. [20] [21] [22] This technique may also be useful for GHM therapy to improve efficiency and minimize leakage to the lungs.
Anastomoses have been described between the anterior interventricular vein and posterior interventricular veins. 23 Using a 1.5-mm coronary balloon inflated in the distal anterior interventricular vein, we prevented GHMs from passing through the latter connection. Distal anterior interventricular vein occlusion appears likely to help improve the efficiency of RI for GHMs. Further studies are needed to investigate whether such measures are essential.
Direct myocardial injection via coronary vein
Direct myocardial injection via the coronary sinus using a Cross point TransAccess catheter has been reported as a novel, feasible method for direct myocardial access. 24 In this study, injections were successfully performed with this technique in all cases without any fatal events.
Catheter-based direct myocardial injections are generally classified into two categories based on approach route: the trans-coronary sinus approach, as used in this study, and the trans-left ventricular approach. A transleft ventricular approach has been reported to result in systemic leakage of injected substances from puncture sites into the greater circulation during systole. 12 From this perspective, the trans-coronary sinus approach may have merit owing to the nature of a venous side approach. Injected GHMs would be squeezed out from the myocardium during systole, but would leak into the pulmonary circulation and be captured in the lungs. Findings of fluorescent signals were detected in the lungs, but not in the liver, kidneys, or spleen, in three of five animals in the DI group, supporting this concept.
In this study, using DI, 50% of injected microspheres were documented to be retained in cardiac tissue. As mentioned above, some injected microspheres may have been squeezed out during systole through needleadvancement sites into the coronary sinus, or may drain through the venous or lymphatic systems. In addition, owing to anatomical features, DI may involve technical difficulties for injecting microspheres to septal walls more than to free-wall regions of the heart. The injection catheter can be advanced to free-wall regions by orienting with the pericardium and LAD, whereas the latter is the only landmark for the septal wall. 24 Technical difficulties with injection into the septal wall may result in extra-myocardial injection of GHMs into the right ventricle with leakage of microspheres into the lungs.
Cardiac delivery of stem cells
Cardiac stem cell therapy has further expanded the field of regenerative medicine. Stem cells can be used to repair cardiac tissue damage. Several clinical trials, 25, 26 and various animal studies, 27, 28 have shown the therapeutic potential of stem cell transplantation. However, there are still unresolved issues in the field of stem cell therapy. 29 One such controversy concerns the route of stem cell delivery to the targeted myocardial area. Although previous studies have shown the feasibility and effectiveness of various catheter-based strategies, 25, 28, 30 current data on safety remains inconsistent as some methods are associated with potential risks such as ventricular arrhythmia, cardiac perforation, or myocardial infarction. 31 Most stem cells commonly used for cardiac stem cell therapy, such as bone marrow-derived mesenchymal stem cells or myoblast, are in the order of micrometer, 31, 32 quite similar in size to the GHMs used in this study. Thus, the present findings provide several new insights regarding current percutaneous delivery strategies in cardiac stem cell therapy. The potential risk of focal-infarctions associated with AI of stem cells highlights an important limitation of this particular percutaneous delivery strategy. Hypothetically, it is plausible that stem cells micro-aggregate following catheter injection. Furthermore, stem cells may share 31 
Limitations
First, the animal model used in this study was a nondiseased heart model, not a diseased model. We focused on whether GHM/bFGF injection with each delivery strategy might cause tissue damage. As a result, we did not use a diseased model that might already involve tissue damage. Angiogenesis is a complex process that involves numerous kinds of growth factors, cytokines, and associated receptors. Expression of these molecules is up-regulated in the ischemic heart despite being insufficient to repair the diseased condition. Exogenous GHM/bFGF injection may thus be more effective in a diseased model than in the present non-diseased model. Further studies are required to evaluate efficacies of GHM therapy in specific models of cardiac disease, such as ischemic heart disease or advanced heart failure models.
Second, we demonstrated that the coronary flow reserve ratio increased in the RI group as well as in the DI group, despite its lower retention efficiency of 10-mm microspheres relative to DI. Differences in distribution of GHM/bFGF complex injected with each of the percutaneous delivery strategy may be a potential explanation. As each strategy distributes GHM/bFGF complex to the heart in its unique way (Figure 3) , variability in effective dosage of GHM/bFGF complex may exist. The discordant results between delivery strategies may also be explained by the use of a single dose of GHM/bFGF complex. Future studies should involve dose-finding experiments to investigate the optimal dosage require to induce angiogenesis regardless of the percutaneous delivery strategy used.
We evaluated the distribution and efficiency of 10-mm microspheres using fluorescent microspheres instead of GHMs. As described above, GHMs are more likely to aggregate than resin microspheres. The data and images shown in the present study might thus represent over-or underestimations of GHM's propensity to aggregate. However, as most of GHMs injected were not aggregated (approximately 10% were aggregated), the images and data were considered suitable to highlight the general features of the three percutaneous strategies to deliver 10-mm GHMs into the heart.
Conclusion
GHMs represent a novel, non-viral vector means to deliver protein or genes to target tissues. Both RI and DI represent effective strategies for the delivery of 10-mm GHMs to the heart, whereas AI seems inappropriate for GHM therapy owing to the risk of focal infarctions. However, both RI and DI result in systemic leakage to the lungs, which may limit applications depending on the genes or proteins injected.
Materials and methods

Experimental study
The study was performed in accordance with the Guidelines for the Care and Use of Laboratory Animals and was approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital. Yorkshire swine (n ¼ 33; body weight, 35-50 kg) were prepared using atropine 0.04 mg/kg and acepromazine 0.1 mg/kg, and then anesthetized using telazol 4.4 mg/kg and xylazine 2.2 mg/kg. Animals were then incubated and ventilated with 100% oxygen and 2% isoflurane. Following sterile skin preparation, a 7-Fr sheath was placed in the right femoral artery, and a 14-Fr sheath was placed in the femoral vein using a standard Seldinger technique. Before catheterization, heparin (5000 U) was injected to maintain an activated clotting time of 250-300 s. Blood pressure, electrocardiography, heart rate, and arterial blood gases were monitored during every procedure.
Preparation of GHM incorporating bFGF
GHMs with a diameter of approximately 10 mm (water content, 95%) were prepared from gelatin with an isoelectric point of 5 (Nitta Gelatin, Osaka, Japan) as described previously. 4 Next, 50 mg of human recombinant bFGF (Kaken Pharmaceutical, Tokyo, Japan) in 10 ml of phosphate-buffered saline was added to 1 mg of dried GHMs to obtain the GHM/bFGF complex. The suspension of GHM/bFGF complex in 5 ml of saline was kept agitated and injected by AI, RI, or DI.
Catheter-based delivery methods Percutaneous coronary artery access. The LAD was canulated using a 7-Fr Hockey Stick-guiding catheter under fluoroscopic guidance. Next, 100 mg of nitroglycerine was injected and baseline coronary angiography was performed.
Percutaneous coronary venous access. Through a 14-Fr sheath, the coronary sinus was selectively cannulated using a pre-formed porcine catheter (Medtronic, MN, USA) and a 0.035-inch hydrophilic exchange wire (Terumo Corporation, Tokyo, Japan). The catheter was then advanced from the coronary sinus to the anterior interventricular vein. Over the exchange wire, a 14-Fr coronary sinus guide catheter with dilator (Medtronic) was delivered to the ostium of the coronary sinus. The exchange wire was then replaced with a 300-cm, 0.014-inch BMW guidewire (Guidant Corporation, CA, USA).
Antegrade injection via coronary artery. A 3.5-mm over-the-wire balloon catheter (Boston Scientific Corporation, MA, USA) was deployed with the guiding catheter in the LAD to the just-distal site of the first diagonal branch. Once the balloon catheter was in place, the guide wire was withdrawn and the balloon catheter slowly inflated to two atmospheres. Occlusion was confirmed by angiography. Next, 10-mm microspheres diluted in 5 ml saline were slowly injected through the wire lumen of the balloon catheter during occlusion. Total occlusion time was o1 min (Figure 1 ).
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Retrograde injection via coronary vein. A 5-Fr 110-cm wedge-balloon (ARROW International, PA, USA) was advanced to the proximal anterior interventricular vein over the 0.014-inch BMW guide wire through a 14-Fr coronary sinus guide catheter. A 1.5-mm over-the-wire balloon catheter (Boston Scientific Corporation) was also deployed to the distal site of the anterior interventricular vein with another 0.014-inch guide wire. A 3.5-mm over-the-balloon catheter was delivered in the LAD as described for antegrade injection. Balloons at the LAD and distal anterior interventricular vein were inflated to two atmospheres in sequence, followed by wedgeballoon inflation to occlude the proximal anterior interventricular vein. Through the inflated wedge balloon, 10-mm microspheres diluted in 5 ml saline were injected (Figure 1 ). Total occlusion time was o1 min.
Direct myocardial injection via coronary vein. Direct myocardial injection via coronary vein was performed as previously reported. 24 In brief, a 6-Fr TransAccess CrossPoint-CX catheter (Medtronic) was advanced into the mid-anterior interventricular veinover the 0.014-inch BMW guide wire through a 14-Fr coronary sinus-guiding catheter. Under intravascular ultrasound guidance, the TransAccess CrossPoint-Cx catheter was oriented toward the anterior or septal wall, and the nitinol needle was extended into the myocardium. A 27-gauge MicroLume Infusion catheter (TransVascular, CA, USA) was advanced through the needle and into the myocardial tissue. The 10-mm microspheres diluted in 5 ml saline were injected at 50 sites (0.1 ml/site) through the microinfusion catheter (Figure 1 ).
Percentage of GHMs aggregated
GHMs were suspended in 5 ml saline and thoroughly mixed. A volume of 10-ml of the suspension was examined using a standard hemocytometer. Then total numbers of GHMs were counted on the nine square of the hemocytometer. Percentages of aggregated GHMs were obtained by dividing numbers of GHMs aggregated by the total numbers of GHMs on the same regions, then multiplying the result by 100.
Distributions of injected microspheres
All fluorescent images were taken using a surgical in vivo imaging system. 33 Red-fluorescent 10-mm microspheres with 580 nm excitation and 605 nm emission wavelength (3.6 Â 10 6 /ml, 5 ml) (Molecular Probes, OR, USA) were injected into the hearts of 15 swine (n ¼ 5 for each strategy; body weight, 35-50 kg). At 10 min after injection, pigs were euthanized and hearts were excised. After taking surface images of whole hearts, hearts were cut into 1-cm slices perpendicular to the atrioventricular groove, and slice images were acquired to visualize the distribution of injected microspheres. Images of the lungs, liver, kidneys, and spleen were also evaluated to detect microspheres that had leaked from the heart.
Quantification of microspheres retained in the heart
After images were acquired, hearts were dissolved at 1 g of heart per 3 ml of 4 M KOH at 371C for 24 h. After nondissolved fat and particulates were removed, 250 ml/well of solution was placed in black 96-well plates (#7701-2350; Whatman, NJ, USA). Fluorescent signals were read using a SpectraMAX GeminiXS spectrofluorometer (Molecular Devices, CA, USA) using a nine-point wellscan method, excitation wavelengths of 580 nm, emission wavelengths of 605 nm, and cutoff filters of 590 nm. Readings were then compared to similarly prepared control heart tissue standards spiked with microspheres to translate fluorescent signals into a number of beads per gram of heart tissue.
Biological efficacy for inducing angiogenesis
Either GHM/bFGF complex (1.0 mg/50 mg) or only GHMs (1.0 mg) in 5 ml of saline were injected into the anterior territory of the heart in 18 swine (body weight, 35-50 kg; n ¼ 5 for each injection of GHM/bFGF complex, and n ¼ 3 for sham injections) with the three injection methods. Animals were then maintained for 1 week. Each swine received oral aspirin 162 mg/day and oral clopidogrel 75 mg/day before complex injection, and for the subsequent week. To evaluate biological efficacy for inducing angiogenesis, coronary flow reserve was measured before and 1 week after injection. Pigs were then euthanized and hearts were excised for histological assessment.
Coronary flow reserve
Coronary flow reserve was measured in the mid part of the LAD and the LCX using a 0.014-inch Coronary Flow Wire (Volcano Therapeutic, CA, USA) and a Flowmap velocity calculation system (Endosonics, CA, USA). Intra-coronary adenosine (18 mg) was given to induce pharmacological hyperemia. Coronary flow reserve in the LAD was normalized to that in the LCX to provide the final coronary flow reserve ratio.
Histological assessment
Square transmural sections (1 Â 1 cm) were cut at the mid-anterior wall and at the posterior wall, and were fixed with 10% buffered formalin for hematoxylin-eosin (H&E) and anti-lectin antibody staining. The percentage of lectin-stained area was calculated for 10 random fields on each slide at Â 200 magnification, and mean values were calculated to assess capillary density. Capillary density in the LAD region was normalized to that in the LCX region to provide capillary density ratio. If fibrosis was detected on H&E staining, the area was measured on each slide at Â 10 magnification, and was calculated as infarction area by dividing it by total area of interest. All histological measurement was performed by a pathologist blinded to treatment allocations.
Euthanasia
Upon protocol completion, all study animals were killed using a bolus of intravenous pentobarbital (100 mg/kg).
Statistical analysis
Statistical analyses were performed using StatView 5.0 software (SAS Institute, NC, USA). Analysis of variance (ANOVA) was used for comparisons among groups for continuous variables. Changes in parameters between points at baseline and 1 week after injection were analyzed using Student's paired t-tests. Data are expressed as means7s.d. Values of Po0.05 were considered statistically significant.
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